Akebia Therapeutics trades as part of the biotechnology industry and is in the healthcare sector. The company CEO is John P. Butler. Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor HIF biology.
Previous Intraday Performance:
The AKBA shares had a previous change of -4.76% which opened at 7.60 and closed at 7.21. It moved to an intraday high of 7.71 and a low of 7.13.
SeekingAlpha: Vifor Pharma and Akebia expands licence agreement
Over the last five trading days, AKBA shares returned -5.13% and in the past 30 trading days it returned -3.09%. Over three months, it changed 17.43%. In one year it has changed -27.54% and within that year its 52-week high was 11.60 and its 52-week low was 5.20. AKBA stock is 38.65% above its 52 Week Low.
Our calculations result in a 200 day moving average of 7.94 and a 50 day moving average of 7.33. Right now, AKBA stock is trading -9.20% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
The company has a market cap of $844.5m with 117.1m shares outstanding and a float of 115.5m shares. Trading volume was 1,495,965 shares and has experienced an average volume of 1,557,407 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for Akebia Therapeutics was -2.47 which ended on 31st of December 2018. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.38.
Base on our calculations, the intrinsic value per share is 36.33, which means it might be undervalued and has a margin of safety of 80.15%
The next earnings report will be: 04-23-2019
The long-term trend of the EPS is an important number as it indicates the present value of Akebia Therapeutics; it is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -14.10% over the last twelve months.
Indicators Also to Watch:
Based on the latest filings, there is 2.90% of insider ownership and 88.80% of institutional ownership.
I calculated the beta to be 1.44
Based on last reported financials, the company’s return on equity is -37.86%, return on assets is -21.10%, profit margin is -74.27%, price-to-sales is 5.48 and price-to-book is 1.33.
Company Score Card:
Results are out of six:
6 : Growth Expectations Result
5 : Financial Safety Result
0 : Past Performance Result
3 : Valuation Result
0 : Dividend Safety Result
3 : Overall Result